https://www.selleckchem.com/pr....oducts/a-438079-hcl.
utcomes were worse in women receiving neoadjuvant chemotherapy. CONCLUSIONS Compared to other races, African American women with advanced ovarian cancer are more likely to receive neoadjuvant chemotherapy than primary debulking surgery and had a higher 90-day mortality rate. In African American women there was no difference in outcomes based on treatment type. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.BACKGROUND There is a lack of evidence in support of any prophylactic measure to prev
Like
Comment
Share
